Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice

Validation Score: 0.900 Price: $0.50 Alzheimer's disease APP/PSEN1/GD3S-/- triple-transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting St8sia1 in APP/PSEN1/GD3S-/- triple-transgenic mice. Primary outcome: reference-memory task performance

Description

Triple-transgenic mice (APP/PSEN1/GD3S-/-) were generated by crossing APP/PSEN1 Alzheimer's disease model mice with GD3S knockout mice. These triple-mutant mice, along with control groups including wild-type, GD3S-/-, and APP/PSEN1 double-transgenic mice, were subjected to a battery of reference-memory tasks to assess cognitive function. The behavioral testing aimed to determine whether elimination of GD3S could rescue the memory impairments typically observed in APP/PSEN1 mice. The experiment demonstrated that while APP/PSEN1 mice showed robust memory deficits, the triple-mutant mice performed at normal levels comparable to wild-type and GD3S-/- controls.

TARGET GENE

St8sia1

MODEL SYSTEM

APP/PSEN1/GD3S-/- triple-transgenic mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

amyloid processing and ganglioside biosynthesis pathways

SOURCE

extracted_from_pmid_18258340

PRIMARY OUTCOME

reference-memory task performance

Scoring Dimensions

📖 Wiki Pages

PSEN1 (Redirect)redirect APP Amyloid Pathway in Alzheimer's Diseasemechanism PSEN1-Mutant Neuronscell APP Genegene APP — Amyloid Precursor Proteingene APP→Amyloid-beta→Plaque→Alzheimer's Disease Causalpathway APP Arctic Mutation (APP Arctic)disease APP Dutch Mutation (APP Dutch)disease APP Flemish Mutation (APP Flemish)disease PSEN1 Mutations in Alzheimer's Diseasedisease APP Swedish Mutation (APPswe)mutation APP-Overexpressing Neuronscell PSEN1 — Presenilin 1gene APP Gene Dosage Reduction Therapy for Down Syndromidea APP-BACE1-Fe65 Complexmechanism

Protocol

Establish APP/PSEN1/GD3S-/- triple-transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for St8sia1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure reference-memory task performance together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting St8sia1 shifts reference-memory task performance in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (reference-memory task performance) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

HSP90-Tau Disaggregation Complex Enhancement0.575

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.